Clinical Trials Logo
  1. Home
  2. Prosthesis Survival
  3. NCT02409186

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Prosthesis Survival Clinical Trial

Official title:
A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Clinical Trial Summary

Esophageal cancer is the sixth leading cause of cancer death in worldwide. Over the past 2 decades, well-designed clinical trials have documented the clinical benefits of combination of chemotherapy and radiation for localized esophageal cancer, either as primary therapy or in neoadjuvant setting. Paclitaxel, a radiation sensitizer, has important single-agent activity in esophageal cancer. Paclitaxel-based chemoradiation has been the framework for the recent Radiation Therapy Oncology Group (RTOG) trials of nonoperative management of esophageal cancer. Accumulating clinical evidence suggests that Epidermal Growth Factor Receptor (EGFR) represents a viable target in the treatment of esophageal cancer. EGFR expression is associated with poor prognosis. Nimotuzumab binds specifically to EGFR on both normal and tumor cells and competitively inhibits the binding of Epidermal Growth Factor (EGF) and other ligands, such as Transforming Growth Factor-α (TGF-α). Preclinical models have suggested synergy between nimotuzumab, paclitaxel, cisplatin and radiation. For our phase II study in locally advanced esophageal squamous cell carcinoma (ESCC), the combination of cetuximab and chemoradiotherapy has demonstrated both response and survival benefits. Myara et al reported that nimotuzumab plus concurrent chemoradiation therapy (CCRT) was safe and provided statistically significant objective response (47.8%) and disease control rate (60.9%) in nonresectable ESCC. With all these, the investigators plan to study phase III trial.

Clinical Trial Description

The primary endpoint of this study is overall survival, and the primary hypothesis is the experimental arm will improve median survival time (MST) from 18.2 month to 28.5 month. Assuming bilateral ɑ = 0.05, statistical power of 80%.Each group requires a minimum of 59 cases. Consider the 20% loss factor.The total sample size is 200 cases.It is 100 cases in each group. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02409186
Study type Interventional
Source Shandong Cancer Hospital and Institute
Contact Jinming Yu, Ph.D, M.D
Phone 13806406293
Email jn7984729@public.jn.sd.cn
Status Recruiting
Phase Phase 3
Start date March 2015
Completion date December 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT03041597 - Dental Implant Supported Removable Dental Prostheses N/A
Enrolling by invitation NCT05589519 - Partial Implant-supported Rehabilitation Using PEEK N/A
Recruiting NCT05649085 - Evaluation of Single-unit Implant-supported Prostheses Survival Using CoCr Prosthetic Abutments: Prospective Observational Study
Active, not recruiting NCT05589493 - Hybrid PEEK-Acrylic Resin Prostheses and the All-on-4 Concept for Full-Arch Rehabilitation - Routine Group N/A
Active, not recruiting NCT04374201 - 14y Prospective Study on Posterior Zirconia-based 3-unit FDPs
Recruiting NCT04688593 - Clinical and Functional Outcome of the MobileLink Acetabular Cup System in the Short-, Mid-, and Longterm Follow-up
Completed NCT04446078 - Hybrid Polyetheretherketone (PEEK)-Acrylic Resin Prostheses and the All-on-4 Concept for Full Arch Rehabilitation N/A
Active, not recruiting NCT05261204 - Transcatheter Aortic Valve Implantation Versus Standard Surgical Aortic Valve Operation
Active, not recruiting NCT06114069 - Prosthetic Management of All on Four Versus All on Six to Rehabilitate Completely Edentulous Maxillary Ridge Opposed by Natural Teeth N/A
Enrolling by invitation NCT05589545 - PEEK Prostheses in the All-on-4 Concept Using Zygomatic Implants for Full-arch Rehabilitation. N/A
Completed NCT04748458 - Long-term Outcomes of Conical Tapered Stems in Cementless Total Hip Arthroplasty Due to Congenital Hip Pathologies
Completed NCT02931903 - Lithium Disilicate Glass-ceramic Versus Hybrid Ceramic Superstructure Materials on Implant Stability N/A
Completed NCT01918124 - A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer Phase 2
Recruiting NCT04960098 - Patient-reported Outcome Measures in Patient Underwent Total Hip and Knee Arthroplasty
Completed NCT04773873 - Implant Retained CAD-CAM Ceramic Crowns N/A
Not yet recruiting NCT02941575 - Patient Satisfaction and Peri-Implant Tissue Success of Hybrid Ceramic Versus E-Max Superstructures N/A
Completed NCT00374946 - A Clinical Evaluation of Wear Couples in THA N/A
Completed NCT04244929 - Multicenter Perspective Study: Clinical Evaluation of the Persona MC® With Preservation or Sacrifice of the PCL N/A
Enrolling by invitation NCT05589506 - Partial Rehabilitation Using a PEEK-acrylic Resin Removable Partial Denture N/A
Enrolling by invitation NCT05589532 - Single Tooth Implant-supported Fixed Prosthetic Rehabilitation Using PEEK. N/A